NCT00692640View on ClinicalTrials.gov

Safety Study of XL147 (SAR245408) in Combination With Erlotinib in Adults With Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

May 31, 2008

Primary Completion Date

November 30, 2011

Study Completion Date

November 30, 2011

Conditions
CancerNon-small Cell Lung Cancer
Interventions
DRUG

XL147 (SAR245408)

Gelatin capsules supplied in 25-mg and 100-mg strengths; daily dosing for 21 days/7 days off

DRUG

Erlotinib

Tablets supplied in 25-mg, 100-mg, and 150-mg strengths; daily dosing

Trial Locations (1)

37203

Investigational Site Number 1214, Nashville

Sponsors

Lead Sponsor

Sanofi
All Listed Sponsors
lead

Sanofi

INDUSTRY